SEC Investigates Dendreon

At least it is an informal probe into the goings on at DNDN.

Dendreon reported multiple insider sales from April to May 9--when the
U.S. Food and Drug Administration ultimately denied the prostate-cancer drug an
immediate approval. For instance, on April 2, Chief Executive Mitchell
Gold sold 202,000 shares at $13.46 for a profit of $2.7 million.
Two other directors also unloaded shares during this period.

It looks like the CEO may get accused of selling some shares ahead of the tape. I should have bought even more puts then I already had if I knew this was happening.